AJAjit Kumar Jha

Ajit Kumar Jha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ajit Kumar Jha has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Anup Kumar

    Department of Biostatistics and Health Informatics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    2 shared publications
  • Zia Hashim

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    2 shared publications
  • Ajmal Khan

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    1 shared publication
  • Ajmal Khan

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

    1 shared publication
  • Alok Nath

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    1 shared publication
  • Alok Nath

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow

    1 shared publication

Latest Publications

  • Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis

    by Zia Hashim, Robert P. Baughman, Ritesh Agarwal, Naresh Kumar Tripathy, Mansi Gupta, Ajmal Khan, Ajit Kumar, Anup Kumar, Alok Nath


  • Open Access

    Prevalence of Relapse in Pulmonary Sarcoidosis: A Systematic Review

    by Zia Hashim, Robert Baughman, Ritesh Agarwal, Naresh Kumar Tripathy, Mansi Gupta, Ajmal Khan, Ajit Kumar Jha, Anup Kumar, Alok Nath

    Background and objectiveRelapse after treatment discontinuation or reduction frequently occurs in pulmonary sarcoidosis (PS), but reported rates vary widely. We conducted a systematic review and meta-analysis to estimate relapse prevalence and evaluate risk factors.MethodsWe searched PubMed, Embase, Scopus, and Google Scholar from inception through January 2026 for studies reporting relapse prevalence in PS. Two reviewers independently extracted data on relapse prevalence, timing, definitions, and predictors, and assessed study quality using the Hoy et al. tool. We calculated pooled prevalence using random effects models, assessed heterogeneity using I2, and performed subgroup analyses and meta-regression.ResultsWe included 51 studies comprising 6076 patients; 3682 were followed up, and 1442 relapsed. Pooled relapse prevalence was 0.39 (95% CI, 0.33-0.45) with substantial heterogeneity (I2=94%). Relapse prevalence was lower in prospective (0.31, 95% CI: 0.25-0.37) than retrospective (0.45, 95% CI: 0.36-0.54) studies. Only 23 (45%) studies provided explicit relapse definitions, which varied across clinical, radiological, functional, and biomarker criteria. Advanced radiographic stage was associated with higher relapse odds than stage I (log OR 0.55-1.04, p<0.05), and Black race with higher odds than White race (log OR 0.91, p<0.01). Relapse prevalence did not differ between clinical-only versus composite definitions.ConclusionsApproximately two-fifths of PS patients relapse after treatment reduction or discontinuation. Marked heterogeneity in relapse definitions and observational study designs underscores the need for standardized criteria. Clinical assessment appears comparable to complex definitions for assessing relapse.